Market Overview

UPDATE: Wedbush Assumes Coverage On Noravax, Inc. As Stock Gears Up For Catalyst-Rich 2015


In a report published Friday, Wedbush Securities analyst Heather Behanna assumed coverage on Noravax, Inc. (NASDAQ: NVAX) with an Outperform rating and $10.00 price target, down from $12.00.

In the report, Wedbush Securities noted, “Novavax's analyst day next week should provide clarity on timelines for abusy 2015. Novavax is gearing up for three trials for its RSV vaccine program by year end; it has begun a proof-of-concept study for maternal immunization and will initiate studies in both pediatric and elderly populations. A dose confirmation study of its retooled quadrivalent flu vaccine will also be initiated this year; all four studies should read out data in 2015, driving value for Novavax.”

Noravax, Inc. closed on Thursday at $4.59.

Latest Ratings for NVAX

Dec 2020JefferiesInitiates Coverage OnBuy
Nov 2020HC Wainwright & Co.MaintainsBuy
Aug 2020HC Wainwright & Co.MaintainsBuy

View More Analyst Ratings for NVAX
View the Latest Analyst Ratings


Related Articles (NVAX)

View Comments and Join the Discussion!

Posted-In: Heather Behanna Wedbush SecuritiesAnalyst Color Initiation Analyst Ratings

Latest Ratings

MRTXHC Wainwright & Co.Maintains257.0
NVDATruist SecuritiesMaintains672.0
BLKBMO CapitalMaintains715.0
BLKDeutsche BankMaintains838.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at